subscribeSubscribe
Bioverativ`s Biologic Enjaymo (sutimlimab) Receives Approval in the U.S.

Bioverativ`s Biologic Enjaymo (sutimlimab) Receives Approval in the U.S.
FDA
09 Feb 2024
Share Share
Bioverativ`s Biologic Enjaymo ( Sutimlimab) Receives Approval in the U.S.

Bioverativ`s Biologic Enjaymo ( Sutimlimab) Receives Approval in the U.S.
FDA
25 Jan 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
Therapeutic-first for cold agglutinin disease haemolytic anaemia

Therapeutic-first for cold agglutinin disease haemolytic anaemia
EUROPEANPHARMACEUTICALREVIEW
21 Nov 2022
Share Share
EC approves Enjaymo for treatment of hemolytic anemia

EC approves Enjaymo for treatment of hemolytic anemia
PRESS RELEASE
17 Nov 2022
Share Share
Genzyme`s Enjaymo (sutimlimab) Receives Approval in the Europe

Genzyme`s Enjaymo (sutimlimab) Receives Approval in the Europe
EMA
17 Nov 2022
Share Share
EMA committee recommends Sanofi’s Enjaymo`s approval for haemolytic anaemia

EMA committee recommends Sanofi’s Enjaymo`s approval for haemolytic anaemia
PHARMABIZ
19 Sep 2022
Share Share
CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved

CHMP recommends approval of Enjaymo™ (sutimlimab), first and only approved
PRESS RELEASE
16 Sep 2022
Share Share
Bioverativ Therapeutics` Biologic Enjaymo (Sutimlimab) Receives Approval in U.S.

Bioverativ Therapeutics` Biologic Enjaymo (Sutimlimab) Receives Approval in U.S.
FDA
04 Feb 2022
Share Share
Sanofi`s treatment for rare anemia hits goal in 2nd phase 3

Sanofi`s treatment for rare anemia hits goal in 2nd phase 3
N. P. Taylor FIERCE BIOTECH
12 Jun 2021
Share Share